← Back
Data updated: Jun 28, 2026
ABSOLUTE AIR, LLC
Pharma Pharmaceuticals
ABSOLUTE AIR, LLC is a pharmaceutical company with 2 FDA-approved products.
2022
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules
ABSOLUTE AIR, LLC's Key Drugs
ABSOLUTE AIR, LLC's core commercial portfolio centers on OXYGEN, USP, NITROGEN, NF — its most strategically important drugs approved in the last 15 years.
ABSOLUTE AIR, LLC's Recent FDA Approvals
New NDA/BLA approvals for ABSOLUTE AIR, LLC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ABSOLUTE AIR, LLC's Therapeutic Areas
Disease areas where ABSOLUTE AIR, LLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ABSOLUTE AIR, LLC Pipeline Snapshot
Active clinical trials for ABSOLUTE AIR, LLC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OXYGEN, USP leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2022-06-10
- Latest
- 2022-06-10
- Applications
- 2